Nisevokitug

Summary

Nisevokitug (CHEMBL4298057) is a phase-3 clinical-stage antibody; indicated across 3 conditions including neoplasm and myelodysplastic syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298057
Name	Nisevokitug
Type	Antibody
Max phase	3

Also known as: Nis-793, NIS-793, Nis793, NIS793, Nisevokitug, NISEVOKITUG

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	2	MONDO:0005070	EFO:0000616
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
primary myelofibrosis	1	MONDO:0009692	MONDO:0044903

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04935359	PHASE3	COMPLETED	Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
NCT04097821	PHASE1/PHASE2	TERMINATED	Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
NCT04390763	PHASE2	TERMINATED	Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT04952753	PHASE2	TERMINATED	Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NCT05546411	PHASE2	TERMINATED	A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
NCT02947165	PHASE1	COMPLETED	Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
NCT04283526	PHASE1	WITHDRAWN	Study of Select Combinations in Adults With Myelofibrosis
NCT04810611	PHASE1	TERMINATED	Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
NCT05417386	PHASE1	TERMINATED	FOLFIRINOX + NIS793 in Pancreatic Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).